

Evolutionary perspective of cancer: myth, metaphors, and reality

Audrey Arnal, Beata Ujvari, Bernard Crespi, Robert Gatenby, Tazzio Tissot, Marion Vittecoq, Paul Ewald, Andreu Casali, Hugo Ducasse, Camille Jacqueline, et al.

▶ To cite this version:

Audrey Arnal, Beata Ujvari, Bernard Crespi, Robert Gatenby, Tazzio Tissot, et al.. Evolutionary perspective of cancer: myth, metaphors, and reality. Evolutionary Applications, 2015, 8 (6), pp.541-544. 10.1111/eva.12265. hal-02502595

HAL Id: hal-02502595 https://hal.umontpellier.fr/hal-02502595

Submitted on 9 Mar 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Evolutionary Applications ISSN 1752-4571

PERSPECTIVE

Evolutionary perspective of cancer: myth, metaphors, and reality

Audrey Arnal, ^{1,2} Beata Ujvari, ^{3,*} Bernard Crespi, ^{4,*} Robert A. Gatenby, ⁵ Tazzio Tissot, ^{1,2} Marion Vittecoq, ^{1,2,6} Paul W. Ewald, ⁷ Andreu Casali, ⁸ Hugo Ducasse, ^{1,2} Camille Jacqueline, ^{1,2} Dorothée Missé, ^{1,2} François Renaud, ^{1,2} Benjamin Roche ^{1,2,9} and Frédéric Thomas ^{1,2}

- 1 MIVEGEC, UMR IRD/CNRS/UM 5290, Montpellier Cedex 5, France
- 2 CREEC, Montpellier Cedex 5, France
- 3 Centre for Integrative Ecology, School of Life and Environmental Sciences, Deakin University, Waurn Ponds, Vic., Australia
- 4 Department of Biological Sciences, Simon Fraser University, Burnaby, BC, Canada
- 5 Department of Radiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
- 6 Centre de Recherche de la Tour du Valat, Arles, France
- 7 Department of Biology and the Program on Disease Evolution, University of Louisville, Louisville, KY, USA
- 8 Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain
- 9 International Center for Mathematical and Computational Modelling of Complex Systems (UMI IRD/UPMC UMMISCO), Bondy Cedex, France

Keywords

adaptationism, cancer, evolutionary processes.

Correspondence

Frédéric Thomas, 911 Avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5, France.

Tel.: +33-4-67416318 fax: +33-4-67416330 e-mail: frederic.thomas2@ird.fr

*Equal contribution.

Received: 20 March 2015 Accepted: 14 April 2015

doi:10.1111/eva.12265

Abstract

The evolutionary perspective of cancer (which origins and dynamics result from evolutionary processes) has gained significant international recognition over the past decade and generated a wave of enthusiasm among researchers. In this context, several authors proposed that insights into evolutionary and adaptation dynamics of cancers can be gained by studying the evolutionary strategies of organisms. Although this reasoning is fundamentally correct, in our opinion, it contains a potential risk of excessive adaptationism, potentially leading to the suggestion of complex adaptations that are unlikely to evolve among cancerous cells. For example, the ability of recognizing related conspecifics and adjusting accordingly behaviors as in certain free-living species appears unlikely in cancer. Indeed, despite their rapid evolutionary rate, malignant cells are under selective pressures for their altered lifestyle for only few decades. In addition, even though cancer cells can theoretically display highly sophisticated adaptive responses, it would be crucial to determine the frequency of their occurrence in patients with cancer, before therapeutic applications can be considered. Scientists who try to explain oncogenesis will need in the future to critically evaluate the metaphorical comparison of selective processes affecting cancerous cells with those affecting organisms. This approach seems essential for the applications of evolutionary biology to understand the origin of cancers, with prophylactic and therapeutic applications.

Introduction

Following the pioneer works of Cairns (1975) and Nowell (1976), cancer is perceived as a phenomenon whose origins and dynamics result from evolutionary processes (Cairns 1975; Nowell 1976; Merlo et al. 2006; Greaves and Maley 2012; Thomas et al. 2013). Placing cancer in an evolutionary ecology landscape is not a semantic problem, but rather a necessity to understand the origins and progression of

cancer with the ultimate aim of developing ways to control neoplastic progression and, most importantly, to prevent cancer and improve therapy when cancer occurs (Aktipis and Nesse 2013; Thomas et al. 2013). Because cancer cells abort their altruistic behavior in favor of a selfish life history strategy (that may eventually involve clonal cooperation), their evolution becomes, at least partially, governed by the same rules that apply to any autonomous entity prioritizing to maximize its own individual fitness. Several

authors proposed that insights into evolutionary and adaptation dynamics of cancers can thus be gained by studying the evolutionary strategies of organisms (Deisboeck and Couzin 2009; Lambert et al. 2011; Ben-Jacob et al. 2012; Sprouffske et al. 2012; Korolev et al. 2014). Although this reasoning is fundamentally correct, in our opinion, it contains a potential risk of excessive adaptationism, potentially leading to the suggestion of complex adaptations that are unlikely to evolve among cancerous cells. Determining the limits of adaptation resulting from oncogenic selection (sensu Ewald and Swain Ewald 2013), and more generally the differences (as well as similarities) between cancer cell and organismal evolution, is fundamental to the applications of evolutionary biology to carcinogenesis and has direct implications for therapies designed to thwart cancer cell proliferation.

What are the primary differences between cancers and organisms, with regard to evolution and adaptation? First, cancer is an ancestral disease that probably developed almost immediately following the transition from unicellular to metazoan life, about one billion years ago (Domazet-Loso and Tautz 2010), but each cancer must 'reinvent the wheel' because their evolutionary products die within the host. Malignant cells are, at the best, under selective pressures for their altered lifestyle for only few decades, and a few dozen or hundreds of cell generations, and even less when the cancer itself reduces the lifespan of its host; for example, only 45 generations of replication are required, in principle, to go from a single cell to the 35-40 trillion cells in the human body. In this context, despite the rapid evolution of malignant cells, not all adaptive responses observed in (rapidly) reproducing unicellular organisms exposed to natural selection over tens of thousands to millions of years can be applied to cancer cells with short life histories. For instance, it has been argued that relatedness within tumors should influence cell decision to migrate (metastasize) and/ or to locally cooperate (Deisboeck and Couzin 2009; Taylor et al. 2013). Such behavioral responses indeed exist in some animal species and microbes (West et al. 2006) to reduce competition and/or to promote the fitness of related individuals (Kawata 1987; Le Galliard et al. 2003; Moore et al. 2006). However, these life history strategies are the result of Darwinian evolution occurring over thousands and/or millions of years, not over mere decades. Unless ancestral heritable traits acquired prior to multicellularity are reactivated in cancerous cells, it is very unlikely that malignant cells would be able to display adaptive responses necessitating the ability of recognizing related conspecifics and adopting accordingly behaviors that depends on the kin context. Additional examples arise from the multistep process of metastasis. Studies have been arguing that the production and dissemination of metastatic cells should be counter selected at the initiation and early stages of tumors due to

local resource availability (the selection should favor cells resistant to anoikis (programmed cell death) and contact inhibition, but with no migratory potential (Gatenby and Gillies 2008). At later stages when damage to the tumor accommodating organ significantly restricts resource availability, tumor cells with increased motility should have selective advantage (and higher fitness) despite the cost of most migrating cells dying without establishing a new colony (Merlo et al. 2006). However, recent studies challenge the traditional view of a late acquisition of metastatic potential and instead propose that tumor cells acquire the motile phenotype early in tumorigenesis (Eyles et al. 2010) as a result of selection favoring expansion of primary tumors. Pathologic cell mobility could indeed contribute significantly not only to metastasis but also to primary tumor growth (cancer self-seeding theory (Norton and Massagué 2006)), but the pathways to the self-seeding that the primary tumor will take depends on the cues and concomitant selective forces of tumor microenvironment. Welcoming nutrient rich or hostile-depleted primary tumor site will result in different outcomes (i) dislodging, then reattaching in/at the primary site, (ii) dislodging, circulation in blood stream then reattachment in/at the primary site, (iii) dislodging, circulation in blood stream then reattachment in a novel (metastatic) site (Norton and Massagué 2006).

Variability in temporal resource quality generating different selection pressures, and resulting in phenotypic divergence, including sympatric speciation, has been observed in numerous species (Ehlinger 1990; Spinks et al. 2000; Garant et al. 2005). However, in our mind, the relevance of these examples to cancer remains questionable because they involve adaptive context-dependent behaviors that result from long-term evolutionary processes, at least more than a few years or decades. The extent to which the context-dependent behaviors can be favored during oncogenic selection remains to be determined. Second, cancer cell evolution through oncogenic selection involves different mechanisms for the generation of genetic and phenotypic variability than organismal evolution: cancer cell lineages are asexual, they undergo very high rates of mutation often due to genomic instabilities, and the mutations and epimutations generated most commonly involve losses of gene functions and large alterations to gene dosages, rather than the small alterations to functions and dosages that appear to typify adaptive organismal evolution. Organismal adaptations often involve changes to cellular regulation that decrease cellular reproduction (e.g., through cell cycle arrest) and survival (e.g., through apoptosis) when such regulation increases the evolutionary fitness of the organism; selection during oncogenesis, however, typically favors abrogations of these regulatory adaptations (Ewald and Swain Ewald 2013). Selection during oncogenesis is therefore commonly destructive of organismal adaptations. Because destructive mutations are more common than mutations that generate or improve sophisticated biological mechanisms, mutation-driven evolution of cancer is feasible over short periods of time. The genomic variability of cancer cells, which may be due to mutagenic microenvironments favoring deficiencies in DNA repair (Breivik 2011), is among the causes of both malignancy itself and failures of chemotherapy due to evolved resistance (Merlo et al. 2006). Given that most mutations are deleterious to cell survival or replication, especially high variability must by first principles reduce the probability, precision, and sustainability of adaptive evolution in the context of complex fits to the environment. A possible example could be the neovascularization in cancer which involves the evolution of structures that are similar to blood vessels but less effective at transport because of aberrant angioarchitecture (Nagy et al. 2010). Larger mutations, as expected under genomic instabilities, are also expected to be less likely to generate adaptive change (Orr 2005). Asexual reproduction will also prevent or delay the coincidence of adaptive gene combinations within individual cells and thus should, in theory, hinder or delay the evolution of adaptations that rely on epistatic effects (De Visser and Elena 2007). Cancer cell populations surmount such population-genetic challenges, in part, through their very large population sizes, which greatly increase the scope for rare, favored alterations and reduce the efficacy of drift.

Contagious cancers [Tasmanian devil facial tumor disease (DFTD) and canine transmissible venereal tumor (CTVT) (Morgia et al. 2006; Murchison 2009)] present unique exceptions to the expectation, based on these considerations, of reduced adaptive evolution in cancer cells. In such cancers, fitness is not restricted by the death of the host, and the transmission of these clonal cancer cell lineages ensures their survival even after the carrying animal succumbs to the disease. CTVT and DFTD are the two oldest naturally occurring cancer cell lines, appearing approximately 11 000 and 20 years ago, respectively (Hawkins et al. 2006; Murchison et al. 2014). The evolutionary history of these cancers has allowed the development, pursuance, and implementation of highly elaborate adaptive strategies that maintain reproductive potential in the hostile micro- (stroma) and macro- (host's genotype) environment of their canine and devil hosts.

Finally, even though cancer cells can theoretically display highly sophisticated adaptive responses, it would be crucial to determine the frequency of their occurrence in patients with cancer, before therapeutic applications can be considered.

The extent to which selection akin to Darwinian evolution occurs in tumors is an old debate (Tarin et al. 2005;

Scheel et al. 2007; Talmadge 2007); while it undoubtedly contributes to cancer development and progression (e.g., resistance to therapies), certain adaptive traits including the metastatic cascade could also be explained by phenotypic plasticity rather than selection (Scheel et al. 2007; Gatenby and Gillies 2008; Gatenby et al. 2011). Although the role of phenotypic plasticity in creating pathogenic cell motility is now a generally accepted and well-supported concept (Scheel et al. 2007; Gatenby and Gillies 2008; Gatenby et al. 2011), restrictively using Darwin's theories to explain metastasis would remain a misconception. Therefore, we think that it is important to add and emphasize the risk of excessive adaptationism applied to cancer evolution, and we hope to stimulate additional debate in this topic. Clearly, further work, especially theoretical models, based in population genetics, genomics, and the evolution of adaptation, is necessary to properly address this point.

The evolutionary perspective on cancer has gained significant international recognition over the past decade and, as all novel scientific paradigms, generated a wave of enthusiasm among researchers. The heightened interest is understandable as somatic cellular selection and evolution indeed offer an elegant adaptive explanation for carcinogenesis with its many manifestations (neoangiogenesis, evasion of the immune system, metastasis, and resistance to therapies). However, scientists who try to explain oncogenesis will need to critically evaluate the metaphorical comparison of selective processes affecting cancerous cells with those affecting organisms—both similarities and differences need to be carefully considered. This approach seems essential for the applications of evolutionary biology to understand the origin of cancers, to control neoplastic progression, and to improve therapies.

Competing interests

The authors declare no conflict of interest.

Authors' contributions

AA, BU, BC, RAG, MV, PE, AC, FR, BR, and FT were involved in the drafting of the article. All the co-authors revised the content of the manuscript and approved this version for publication.

Acknowledgements

This work was supported by the ANR (Blanc project EVO-CAN) and by the CNRS (INEE). The CREEC extends its gratitude to its two sponsor companies: SPALLIAN and NEMAUSYS. We also thank the Darwinian Evolution of Cancer Consortium for discussions.

Data archiving statement

Not applicable.

Literature cited

- Aktipis, C. A., and R. M. Nesse 2013. Evolutionary foundations for cancer biology. Evolutionary Applications 6:144–159.
- Ben-Jacob, E., D. S. Coffey, and H. Levine 2012. Bacterial survival strategies suggest rethinking cancer cooperativity. Trends in Microbiology 20:403–410.
- Breivik, J. 2011. Don't stop for repairs in a war zone: Darwinian evolution unites genes and environment in cancer development. Proceedings of the National Academy of Sciences 98:5379–5381.
- Cairns, J. 1975. Mutation selection and the natural history of cancer. Nature **255**:197–200.
- Deisboeck, T. S., and I. D. Couzin 2009. Collective behavior in cancer cell populations. BioEssays 31:190–197.
- De Visser, J. A. G. M., and S. F. Elena 2007. The evolution of sex: empirical insights into the roles of epistasis and drift. Nature Reviews Cancer 8:139–149.
- Domazet-Loso, T. A., and D. Tautz 2010. Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoa. BMC Biology 8:66–76.
- Ehlinger, T. J. 1990. Habitat choice and phenotype-limiter feeding efficiency in Bluegill: individual differences and trophic polymorphism. Ecology 71:886–896.
- Ewald, P., and H. A. Swain Ewald 2013. Toward a general evolutionary theory of oncogenesis. Evolutionary Applications **6**:70–81.
- Eyles, J., A. L. Puaux, X. Wang, B. Toh, C. Prakash, M. Hong, T. Guan Tan, et al. 2010. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. Journal of Clinical Investigation 120:2030–2039.
- Garant, D., L. E. B. Kruuk, T. A. Wilkin, R. H. McCleery, and B. C. Sheldon 2005. Evolution driven by differential dispersal within a wild bird population. Nature 433:60–65.
- Gatenby, R. A., and R. J. Gillies 2008. A microenvironmental model of carcinogenesis. Nature Reviews Cancer 8:56–61.
- Gatenby, R. A., R. J. Gillies, and J. S. Brown 2011. Of cancer and cave fish. Nature Reviews Cancer 11:237–238.
- Greaves, M., and C. C. Maley 2012. Clonal evolution in cancer. Nature 481:306–313
- Hawkins, C. E., C. Baars, H. Hesterman, G. J. Hocking, M. E. Jones, B. Lazenby, D. Mann, et al. 2006. Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii. Biological Conservation 131:307–324.
- Kawata, M. 1987. The effect of kinship on spacing among female redbacked voles, Clethrionomys rufocanus bedfordiae. Oecologia 72:115– 122
- Korolev, K. S., J. B. Xavier, and J. Gore 2014. Turning ecology and evolution against cancer. Nature Reviews Cancer 14:371–380.
- Lambert, G., L. Estévez-Salmeron, S. Oh, D. Liao, B. M. Emerson, T. D. Tlsty, and R. H. Austin 2011. An analogy between the evolution of

- drug resistance in bacterial communities and malignant tissues. Nature Reviews Cancer 11:375–382.
- Le Galliard, J.-F., R. Ferrière, and J. Clobert. 2003. Mother-offspring interactions affect natal dispersal in a lizard. Proceedings of the Royal Society of London. Series B 270:1163–1169.
- Merlo, L. M., J. W. Pepper, B. J. Reid, and C. C. Maley 2006. Cancer as an evolutionary and ecological process. Nature Reviews Cancer **6**:924–
- Moore, J. C., A. Loggenberg, and J. M. Greeff 2006. Kin competition promotes dispersal in a male pollinating fig wasp. Biology Letters 2:17–19
- Murchison, E. P. 2009. Clonally transmissible cancers in dogs and Tasmanian devils. Oncogenes 27:S19–S30.
- Murchison, E. P., D. C. Wedge, L. B. Alexandrov, B. Fu, I. Martincorena, Z. Ning, J. M. C. Tubio, et al. 2014. Transmissible dog cancer genome reveals the origin and history of an ancient cell lineage. Science 343:437–440.
- Morgia, C., J. K. Pritchard, S. Y. Kim, A. Fassati, and R. A. Weiss 2006. Clonal origin and evolution of a transmissible cancer. Cell **126**:477–487.
- Nagy, J. A., S. H. Chang, S. C. Shih, A. M. Dvorak, and H. F. Dvorak 2010. Heterogeneity of the tumor vasculature. Seminars in Thrombosis and Hemostasis 36:321–331.
- Norton, L., and J. Massagué 2006. Is cancer a disease of self-seeding? Nature Medicine 12:875–878.
- Nowell, P. C. 1976. The clonal evolution of tumour cell populations. Science 194:23–28.
- Orr, H. A. 2005. The genetic theory of adaptation: a brief history. Nature Reviews Genetics **6**:119–127.
- Scheel, C., T. Onder, A. Karnoub, and R. A. Weinberg 2007. Adaptation versus selection: the origins of metastatic behavior. Cancer Research 67:11476–11479.
- Spinks, A. C., J. U. M. Jarvis, and N. C. Bennett 2000. Comparative patterns of philopatry and dispersal in two common mole-rat populations: implications for the evolution of mole-rat sociality. Journal of Animal Ecology 69:224–234.
- Sprouffske, K., L. M. Merlo, P. J. Gerrish, C. C. Maley, and P. D. Sniegowski 2012. Cancer in light of experimental evolution. Current Biology 22:R762–R771.
- Talmadge, J. E. 2007. Is metastasis due to selection or adaptation? Clonal selection of metastasis within the life history of a tumor. Cancer Research 67:11471–11475.
- Tarin, D., E. W. Thompson, and D. F. Newgreen 2005. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Research 65:5996–6000.
- Taylor, T. B., L. J. Johnson, R. W. Jackson, M. A. Brockhurst, and P. R. Dash 2013. First steps in experimental cancer evolution. Evolutionary Applications 6:535–548.
- Thomas, F., D. Fisher, P. Fort, J. P. Marie, S. Daoust, B. Roche, C. Grunau, et al. 2013. Applying ecological and evolutionary theory to cancer: a long and winding road. Evolutionary Applications 6:1–10.
- West, S. A., A. S. Griffin, and A. Gardner 2006. Social semantics: altruism, cooperation, mutualism, strong reciprocity and Group selection. Journal of Evolutionary Biology **20**:415–432.